<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821872</url>
  </required_header>
  <id_info>
    <org_study_id>7258</org_study_id>
    <nct_id>NCT01821872</nct_id>
  </id_info>
  <brief_title>Paracetamol CSF Pharmacokinetics Study</brief_title>
  <official_title>A Single Centre Prospective Randomised Study to Investigate the Cerebrospinal Fluid (CSF) Pharmacokinetics of Intravenous Paracetamol in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barts &amp; The London NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite its use for decades all over the world, the exact mechanism of action of paracetamol&#xD;
      is not fully understood and essentially involves a combination of hypotheses. It is known to&#xD;
      have an effect via the central nervous system, and of the many mechanisms proposed, one&#xD;
      hypothesis is that it may have indirectly activate CB1 (cannabinoid) receptors, through its&#xD;
      novel metabolite AM404.&#xD;
&#xD;
      This study aims to elucidate cerebrospinal levels of paracetamol and to measure the&#xD;
      concentration of its metabolites, including AM404 in CSF. This may, in turn, give us useful&#xD;
      information on the mechanism of action of paracetamol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing spinal blockade for urological surgery were administered 1g paracetamol&#xD;
      intravenously at varying intervals prior to spinal anaesthesia, at which time 5mls of&#xD;
      cerebrospinal fluid and 10mls of blood were sampled, and analysed for concentrations of&#xD;
      paracetamol, paracetamol glucuronide, paracetamol sulphate, and AM404, a known&#xD;
      endocannabinoid reuptake inhibitor, and metabolite of paracetamol.&#xD;
&#xD;
      Paracetamol readily penetrates into the cerebrospinal fluid in animal studies and in&#xD;
      children. This could account for the rapid central analgesic and antipyretic action of&#xD;
      intravenous paracetamol however this remains to be studied in adults. AM404 has never before&#xD;
      been identified in humans, and its presence in CSF following paracetamol supports the&#xD;
      hypothesis of a central mechanism of action of paracetamol via AM404.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of AM404 in CSF</measure>
    <time_frame>5-211 minutes post-administration of paracetamol</time_frame>
    <description>AM404 is a metabolite of paracetamol thought to be formed in the brain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of paracetamol in plasma and CSF</measure>
    <time_frame>5-211 minutes post administration of paracetamol</time_frame>
    <description>Concentrations of paracetamol measured in plasma and CSF following intravenous paracetamol administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of paracetamol glucuronide and sulphate conjugates in plasma and CSF.</measure>
    <time_frame>5-211 minutes post administration of paracetamol</time_frame>
    <description>Concentrations of glucuronide and sulphate conjugates of paracetamol measured in plasma and CSF following intravenous paracetamol administration.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Paracetamol</condition>
  <arm_group>
    <arm_group_label>Sampling at approx 15 minutes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plasma and CSF samples to be taken at 15 minutes post administration of intravenous paracetamol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sampling at approx 30 minutes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plasma and CSF samples to be taken at 30 minutes post administration of intravenous paracetamol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sampling at approx 120minutes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plasma and CSF samples to be taken at 120 minutes post administration of intravenous paracetamol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of paracetamol</intervention_name>
    <description>Administration of 1g intravenous paracetamol</description>
    <arm_group_label>Sampling at approx 120minutes</arm_group_label>
    <arm_group_label>Sampling at approx 15 minutes</arm_group_label>
    <arm_group_label>Sampling at approx 30 minutes</arm_group_label>
    <other_name>Perfalgan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects aged 18 to 80 years&#xD;
&#xD;
          -  Subjects undergoing surgery who require a spinal anaesthetic and paracetamol as part&#xD;
             of their routine anaesthetic plan&#xD;
&#xD;
          -  Subjects with an American Society of Anesthesiology score of I-III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with any contraindication to spinal anaesthesia&#xD;
&#xD;
          -  Subjects with known clotting abnormalities&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Subjects with known hypersensitivity to paracetamol&#xD;
&#xD;
          -  Patients with severe hepatocellular insufficiency&#xD;
&#xD;
          -  Patients already taking regular doses of paracetamol&#xD;
&#xD;
          -  Any subjects deemed medically unsuitable by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Mehta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pain and Anaesthesia Research Centre, Barts Health NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>March 27, 2013</study_first_submitted>
  <study_first_submitted_qc>March 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2013</study_first_posted>
  <last_update_submitted>April 2, 2013</last_update_submitted>
  <last_update_submitted_qc>April 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>paracetamol</keyword>
  <keyword>acetaminophen</keyword>
  <keyword>AM404</keyword>
  <keyword>CSF</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

